U.S. Disease Researchers Begin Ebola Vaccine Trial
Trial begins as new disease outbreak occurs in Republic of the Congo
A trial of the first experimental vaccine to prevent infection from the deadly Ebola virus began November 18 at the
National Institute for Allergies and Infectious Diseases (NIAID) in Bethesda, Maryland.
The vaccine contains no infectious material from the Ebola virus, but was synthesized using modified, inactivated genes
from the pathogen. According to a NIAID press release, 27 volunteers will be participating in the one-year trial in
which researchers will seek to ascertain the safety of the vaccine.
The vaccine trial begins as the World Health Organization reported the occurrence of 11 cases of Ebola appearing in the
Republic of the Congo November 17. Previous outbreaks in Africa have killed up to 90 percent of those infected.
Considered one of the most deadly diseases known to medical science, Ebola' symptoms are a sudden onset of fever,
weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhea, rash, limited kidney and liver
functions, and both internal and external bleeding.
"An effective Ebola vaccine not only would provide a life-saving advance in countries where the disease occurs
naturally, it also would provide a medical tool to discourage the use of Ebola virus as an agent of bioterrorism," said
NIAID Director Anthony S. Fauci, M.D.
Following is the text of the NIAID press release:
(begin text)
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Nov. 18, 2003
NIAID EBOLA VACCINE ENTERS HUMAN TRIAL
The first human trial of a vaccine designed to prevent Ebola infection opened today. Scientists from the Vaccine
Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National
Institutes of Health (NIH), designed the vaccine, which was administered to a volunteer at the NIH Clinical Center in
Bethesda. The vaccine does not contain any infectious material from the Ebola virus.
Just three years ago, VRC Director Gary Nabel, M.D., Ph.D., together with a team of scientists from the VRC and the
Centers for Disease Control and Prevention, described an experimental Ebola vaccine that fully protected monkeys from
lethal infection by the virus. One component of that vaccine will now be assessed for safety in human volunteers. The
trial vaccine, a type called a DNA vaccine, is similar to other investigational vaccines that hold promise for
controlling such diseases as AIDS, influenza, malaria and hepatitis.
"This trial is further evidence of the ability of the VRC to rapidly translate basic research into tangible products,"
notes NIAID Director Anthony S. Fauci, M.D. "Our accelerated effort to understand and combat Ebola infection is part of
the NIAID commitment to its biodefense mission. An effective Ebola vaccine not only would provide a life-saving advance
in countries where the disease occurs naturally, it also would provide a medical tool to discourage the use of Ebola
virus as an agent of bioterrorism."
Outbreaks of Ebola in Africa kill up to 90 percent of those infected. No effective treatment exists for this highly
infectious disease, which causes extensive internal bleeding and rapid death. According to experts, vaccination is the
best strategy for preventing or containing this deadly infection.
A gap of two decades separated the first Ebola epidemic of 1976 and the next, which arose in 1995. In recent years, for
reasons unknown, outbreaks of Ebola are occurring with increasing frequency.
On November 17, 2003, the World Health Organization reported 11 cases of Ebola hemorrhagic fever in the Republic of the
Congo. Dr. Nabel notes, "The current Ebola outbreak in the Congo provides a stark reminder of the need to rapidly
develop vaccines against such perilous infections. A few years ago, we did not imagine that our vaccine would enter
human trials so quickly, but the re-emergence of such viruses makes it all the more important to respond quickly.
Individuals who volunteer for these vaccine trials can help us understand if our new vaccines ultimately will be
effective."
Twenty-seven volunteers between the ages of 18 and 44 will participate in the study. Six people will receive a placebo
injection and 21 will receive the investigational vaccine, manufactured by Vical Inc., a San Diego biotechnology company
working in collaboration with the VRC. Vical has also secured a nonexclusive license from NIH to proprietary gene
sequences used in the DNA Ebola vaccine. In the new trial, volunteers will receive three injections over two months and
will be followed for one year. Volunteers will not be exposed to Ebola virus. Individuals interested in enrolling in the
trial may visit http://www.clinicaltrials.gov or call the VRC toll-free at 1-866-833-LIFE (5433).
The candidate vaccine is synthesized using modified, inactivated genes from Ebola virus. This gives the immune system
information about viral structures so that it can mount a rapid defense should the real virus ever be encountered. There
is no infectious material in the vaccine, and the virus was not present during any stage of the manufacturing process,
notes Barney Graham, M.D., Ph.D., director of the clinical trials unit of the VRC. "It is impossible for the vaccine to
cause infection," he adds, "because it employs new technology known to safely stimulate broad immune responses."
Besides assessing the vaccine's safety, researchers will also examine the volunteers' blood to look for signs of immune
system reaction to the vaccine. Ultimately, the scientists envision this vaccine as the first in a two-stage vaccination
strategy called prime-boost: after "priming" with the DNA vaccine, the immune system response is "boosted," or
augmented, by a second inoculation with modified, non-disease-causing cold viruses that make selected Ebola proteins.
The booster essentially sets the immune system on alert against future infection by Ebola virus.
In August, Dr. Nabel and his colleagues reported using the booster shot to quickly and completely protect monkeys
against Ebola. A fast-acting vaccine would be of great use during an outbreak of Ebola. The full prime-boost strategy,
which uses the DNA vaccine being tested in this study, elicits a stronger immune response and is important to pursue for
individuals at high risk, such as health care workers. Dr. Nabel says that expanded human trials of Ebola vaccines using
the prime-boost strategy could begin by 2005.
NIAID is a component of the National Institutes of Health (NIH), which is an agency of the Department of Health and
Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious and immune-mediated
illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism,
tuberculosis, malaria, autoimmune disorders, asthma and allergies.
### References: NJ Sullivan et al. Development of a protective vaccine for Ebola virus infection in primates. Nature
408:605-09 (2000). http://www.niaid.nih.gov/newsroom/releases/ebolavacc.htm N. Sullivan et al. Accelerated vaccine for
Ebola virus hemorrhagic fever in non-human primates. Nature 424:681-84 (2003).
http://www.niaid.nih.gov/newsroom/releases/ebolavaccine.htm
For a photo of the Ebola virus, go to http://www.niaid.nih.gov/cgi-shl/newsroom/newsrel.cfm and click on "NIAID Ebola
Vaccine Enters Human Trial"
Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at .